Vasculitis & polymyalgia rheumatica
Benralizumab for eosinophilic granulomatosis with polyangiitis
Authors' conclusion
Benralizumab appears to be an effective treatment for refractory asthma or ENT manifestations in EGPA and allows GC-sparing. However, its efficacy was lower after prior failure of mepolizumab.
Study context
- Population
- Eosinophilic granulomatosis with polyangiitis (EGPA) patients treated with off-label benralizumab
- Participants
- 68 patients
- Exposure
- Prior mepolizumab vs No prior mepolizumab
- Prior mepolizumabn = 31
- Outcome
- Complete response: no disease activity (BVAS=0) and prednisone ≤4 mg/day
Methodological detailsmulticentre, off-label benralizumab
- Multicentre
- Off-label benralizumab
Main finding
As reported in the abstract
Response to benralizumab
Complete response
33
49%
Partial response
24
36%
No response
10
15%
Observational data: associations, not effects.
Further findings
Primary failure by prior mepolizumab use
P = 0.034
GC discontinuation by prior mepolizumab use
P = 0.001
Further line treatments among 57 initial responders
- Required further line treatments
- 10 (18%)
GC discontinuation
- Glucocorticoids (GCs) discontinued
- 23 (38%)
Safety
- Vasculitis flares
- 7 (11%)
- Associated with histological vasculitis and/or ANCA positivity at benralizumab initiation
- P = 0.004
Original publication
Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. Published 7 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →